After reading up on Lawrence Steinman M.D., I wonder if he isn’t a fly in the ointment? I sight the fact that he is the Founder of Bayhill Therapeutics and honored with the 2004 National MS Society/American Academy of Neurology's 2004 John Dystel Prize for Multiple Sclerosis Research, for his major contributions to our understanding of MS-like disease models, and for translating these findings to the clinical development of novel therapeutic strategies for MS. And that $816,750 award is good only until 3/31/10.
Here’s more:
PALO ALTO, Calif.--(BUSINESS WIRE)--April 27, 2004
Professor Lawrence Steinman, MD, of Stanford Medical Center and Founder of Bayhill Therapeutics, has been chosen by a committee of his peers to receive the 2004 John Dystel Prize for Multiple Sclerosis (MS) Research. Dr. Steinman is being honored for his major contributions to scientific understanding of MS-like disease models, and for translating these findings to the development of novel therapeutic strategies for people with MS.
"MS starts in a few trees and then starts burning the whole forest," said Lawrence Steinman, MD, a ...
SAN MATEO, Calif. -- Bayhill Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA[TM] platform to develop novel and targeted autoimmune disease treatments, today announced that Lawrence Steinman M.D., Professor of Neurology, Pediatrics and Genetics at Stanford University and Founder, Director and Scientific Advisory Board Chairman of Bayhill Therapeutics, has been awarded an endowed chair at Stanford as the George A. Zimmerman Professor. Dr. Steinman is the inaugural holder of the chair, funded to support multiple sclerosis (MS) ...
Nuon Therapeutics' founding scientists, Marc Feldmann, MD, PhD and Larry Steinman, MD, have conducted wide-ranging preclinical testing of tranilast.
...
Professor Steinman is professor, Departments of Neurology and Neurological Sciences, Stanford University, and a specialist in multiple sclerosis (MS).His research identified the biological pathways that led to the development the MS therapeutic, Tysabri®.Professor Steinman's work with tranilast showing improvement in an animal model of MS was published in the journal Science.
...
The company's scientific founders are Prof. Larry Steinman at Stanford University, Palo Alto, Prof. Marc Feldmann, Imperial College, London, and Dr. Michael Selley, formerly from the Australian National University.
Collaborative MS Research Center Award
$816,750; 4/1/05-3/31/10
Principal Investigator
Lawrence Steinman, MD
Stanford University, Palo Alto, Calif.
http://www.nationalmssociety.org/resear ... index.aspx
So it will interesting to see if he comes on board with CCSVI, especially if it receives funding, or if he goes looking for more pharma monies.
Lora
>
there is some merit to what he is saying. Given the recent adverse events, it's only prudent to stop these type of procedures unless it is in a clinical trial. The law requires a lot more disclosure to patients in clinical trials as to the known and unknown risks of a new procedure/drug, so it's in the interest of OUR safety that this treatment be done under the umbrella of a clinical trial. 
